Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.35 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | PEPD | P12955 | 1/20 | 0.35 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26029101 | 0.81 | DPP4 (0.44) | MEN1KMT2AMAPK1EPHX2ALDH1A1 | |
| SCHEMBL8105673 | 0.79 | ALDH1A1 (0.51) | MEN1KMT2AEPHX2ALDH1A1NPC1 | |
| SCHEMBL27634517 | 0.71 | CYP19A1 (0.43) | MEN1KMT2AMAPK1EPHX2ALDH1A1 | |
| SCHEMBL5399501 | 0.71 | LMNA (0.42) | MEN1KMT2AMAPK1EPHX2ALDH1A1 | |
| SCHEMBL5671926 | 0.71 | ALDH1A1 (0.47) | MEN1KMT2AEPHX2ALDH1A1MAPT | |
| SCHEMBL3292905 | 0.70 | ALDH1A1 (0.42) | MEN1KMT2AEPHX2ALDH1A1NPC1 | |
| SCHEMBL131064 | 0.69 | CYP17A1 (0.55) | MEN1KMT2AMAPK1EPHX2ALDH1A1 | |
| SCHEMBL17226195 | 0.69 | MEN1 (0.38) | MEN1KMT2AMAPK1EPHX2ALDH1A1 | |
| SCHEMBL27978333 | 0.69 | KMT2A (0.48) | MEN1KMT2AMAPK1EPHX2ALDH1A1 | |
| SCHEMBL15535916 | 0.69 | KMT2A (0.48) | MEN1KMT2AMAPK1EPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1088558-B1 | Galenic formulations comprising paramagnetic and diamagnetic compounds | BAYER SCHERING PHARMA AG (DE) | 2007-06-27 | — | — | EP | disclosed |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-07 | — | — | US | disclosed |
| US-6818203-B2 | COMPLEXES HAVE CRITICAL MICELLE FORMATION CONCENTRATION, HYDRODYNAMIC MICELLE DIAMETER, AND PROTON RELAXIVITY IN PLASMA CONTRAST MEDIA IN MR IMAGING | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-16 | — | — | US | disclosed |
| EP-1307236-A2 | USE OF METAL COMPLEXES CONTAINING PERFLUOROALKYL AS CONTRAST AGENTS IN MR-IMAGING FOR THE REPRESENTATION OF PLAQUES, TUMOURS AND NECROSES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-07 | — | — | EP | disclosed |
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-04-17 | — | — | US | disclosed |
| WO-2002013874-A2 | USE OF METAL COMPLEXES CONTAINING PERFLUOROALKYL AS CONTRAST AGENTS IN MR-IMAGING FOR THE REPRESENTATION OF PLAQUES, TUMOURS AND NECROSES | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-21 | — | — | WO | disclosed |
| EP-1088558-A2 | Galenic formulations | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, PTDSS1 | MEN1 398/4885KMT2A 4662/4885MAPK1 1517/4885 |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, MALT1 | MEN1 242/4885KMT2A 4638/4885MAPK1 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.